ASCO 2020 | FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancers

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, details the May 2020 FDA approval of selpercatinib, a RET inhibitor, in RET fusion positive non-small cell lung cancer (NSCLC), medullary thyroid cancer and RET fusion positive thyroid cancer following the results of the LIBRETTO-001 study (NCT03157128). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).